Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

Launched by IPSEN · Sep 19, 2005

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Patient having documentation supporting diagnosis of active acromegaly in one of the following definitions:
• • patient having received neither somatostatin analogue nor dopaminergic agonist within the previous 12 weeks and having an IGF-1 level at least 1.3 times the upper limit of the age-adjusted normal range,
• • patient being treated with a somatostatin analogue (other than lanreotide autogel) or a dopaminergic agonist when attending the first visit and having at the end of the wash-out period an IGF-1 level at least 1.3 times the upper limit of the age-adjusted normal range.
• Exclusion Criteria:
• • Patient having had pituitary surgery within the previous 3 months
• • Patient having received radiotherapy for acromegaly disease within the previous 36 months
• • Patient being predicted to require pituitary surgery (adenomectomy) or receive radiotherapy during the study period
• • Patient having received lanreotide autogel at any time before the study